Skip to main content

Endo International Value Stock - Dividend - Research Selection

Endo International


Market price date: 16.05.2022
Market price: 1,15 USD

Endo International Fundamental data and company key figures of the share

Annual reports in USD
Key figures 08-03-2022
Cash flow
Net operating cash flow 411.050.000
Capital Expenditures -77.929.000
Free cash flow 333.120.992
Balance sheet
Total Equity -1.243.990.000
Liabilities & Shareholders equity 8.767.420.000
Income statement
Net income -613.245.000
Eps (diluted) -2,630
Diluted shares outstanding 233.578.000
Net sales/revenue 2.993.210.000

Fundamental ratios calculated on: 16-05-2022

Key figures 16-05-2022
Cash flow
P/C 0,65
P/FC 0,81
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization268.614.688,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm , Opana ER, Voltaren Gel, Percocet , Frova , Supprelin LA, Vantas , Valstar and Fortesta Gel. The Company operates in four segments: Endo Pharmaceuticals, Qualitest, AMS, and HealthTronics. Through the Company's HealthTronics segment, the Company provides lithotripsy services, prostate treatment services, anatomical pathology services, medical products manufacturing, sales and maintenance, and information technology solutions. Its products in the Qualitest portfolio includes Endocet, Morphine Sulfate ER, and Hydrocodone. Its AMS products include AMS 700 MS, AMS 800 artificial urinary sphincter, GreenLight XPS laser system, and Monarc subfascial hammock. Its Endo Pharmaceuticals products include Lidoderm, Opana ER, Voltaren Gel, and Percocet.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Is it Still Worth Keeping Your Endo International (ENDP) Shares?

Miller Value Partners, an investment management firm, published its “Income Strategy” first quarter 2022 investor letter – a copy of which can be downloaded here. The Miller Income Strategy returned -10.08% for the first quarter, while the unmanaged high-yield benchmark was down -4.51%. Most asset classes declined, and smaller companies, which make up a large share of the […]

Buxton Helmsley Issues Letter to Endo International Plc. Shareholders and Creditors, Relating to Corporate Malfeasance and False Statements of Financials

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Idaho announces $119 million opioid crisis settlement

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Cable companies to offer effectively free internet to low-income homes

The news means that tens of millions of households could receive high-speed internet at no cost, according to the White House.

Endo price target lowered to $2 from $4 at BMO Capital

BMO Capital analyst Gary ... ENDP

Endo price target lowered to $1 from $2 at Barclays

Barclays analyst Balaji P... ENDP

Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results

Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.

Under Armour, Dish fall; Cigna, NRG Energy rise

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Why Endo International Stock Is Cratering Today

Endo International (NASDAQ: ENDP) stock was cratering on Friday, with shares falling 31.6% as of 11:49 a.m. ET. This result was in line with the consensus estimate. Endo posted adjusted earnings in the first quarter of $155.9 million, or $0.66 per share.